|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-14.22/2.06
|
Enterprise Value
55.70M
|
Balance Sheet |
Book Value Per Share
-9.36
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
53.47M
|
Operating Revenue Per Share
8.35
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. |